Maze Therapeutics’ (MAZE) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $46.00 target price on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Truist Financial dropped their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Trading Down 1.8%

MAZE stock opened at $27.18 on Wednesday. Maze Therapeutics has a twelve month low of $12.81 and a twelve month high of $53.65. The company has a quick ratio of 17.88, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. The firm’s fifty day simple moving average is $27.79 and its two-hundred day simple moving average is $33.03.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). As a group, analysts anticipate that Maze Therapeutics will post -2.74 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the sale, the insider owned 26,250 shares in the company, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 140,674 shares of company stock valued at $3,904,707 over the last 90 days. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the fourth quarter worth $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics during the fourth quarter worth approximately $43,000. California State Teachers Retirement System lifted its stake in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics during the 2nd quarter worth $48,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.